Crossject Société Anonyme (ALCJ.PA)
Paris · EUR · Healthcare · Medical Instruments & Supplies
€1.28 (-0.16%) as of
Key statistics
- Market cap
- 76.91M
- Forward P/E
- 2.45
- EPS (TTM)
- -0.1900
- Dividend yield
- 0.00%
- 52-week range
- 1.1000 – 2.6950
- Beta
- 0.52
- Revenue (TTM)
- 137k
- Profit margin
- 0.00%
- Analyst target
- €4.15
- Volume
- 21.63k
About Crossject Société Anonyme
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures. The company was incorporated in 2001 and is based in Dijon, France.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Headquarters
- Dijon, France
- Employees
- 99
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.